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An H/D exchange- and MALDI mass spectrometry-based screening assay was applied to
search for novel ligands that bind to cyclophilin A, a potential therapeutic and diagnostic
target in lung cancer. The assay is based on stability of unpurified proteins from rates of H/D
exchange (SUPREX), which exploits the H/D exchange properties of amide protons to
measure the increase in a protein’s thermodynamic stability upon ligand binding in solution.
The current study evaluates the throughput and efficiency with which 880 potential ligands
from the Prestwick Chemical Library (Illkirch, France) could be screened for binding to
cyclophilin A. Screening was performed at a rate of 3 min/ligand using a conventional MALDI
mass spectrometer. False positive and false negative rates, based on a set of control data, were
as low as 0% and 9%, respectively. Based on the 880-member library screening, a false positive
rate of 0% was observed when a two-tier selection strategy was implemented. Although novel
ligands for cyclophilin A were not discovered, cyclosporin A, a known ligand to CypA and a
blind control in the library, was identified as a hit. We also describe a new strategy to eliminate
some of the complications related to back exchange that can arise in screening applications of
SUPREX. (J Am Soc Mass Spectrom 2008, 19, 1303–1311) © 2008 American Society for Mass
SpectrometryThe speed and sensitivity of modern mass spec-trometers make them attractive tools for highthroughput screening (HTS) assays, and several
mass spectrometry-based HTS assays have been devel-
oped in recent years [1–3]. We recently reported on a
mass spectrometry-based assay for protein–ligand bind-
ing detection that utilizes an abbreviated version of stabil-
ity of unpurified proteins by rates of H/D exchange
(SUPREX), which is an H/D exchange- and mass
spectrometry-based technique capable of detecting and
quantifying protein–ligand binding interactions [4 –9].
In the abbreviated version of SUPREX (referred to
hereafter as single-point SUPREX), binding events are
detected by measuring the target protein’s mass change
after H/D exchange in a deuterated buffer containing a
specific concentration of a chemical denaturant [10].
Several inherent advantages of SUPREX make it
particularly well-suited for an HTS assay. Unlike most
radiometric or fluorescence-based assays, single-point
SUPREX can be performed on protein–ligand com-
plexes directly in solution without immobilization or
labeling of the target or library compounds. The tech-
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doi:10.1016/j.jasms.2008.06.007nique does not require time-consuming separations or
filtrations and is relatively general (i.e., it can be readily
transferred to most protein–ligand systems). Additional
advantages include the ability to study multicomponent
mixtures and to make measurements on picomole
quantities of protein.
The single-point SUPREX protocol was initially de-
veloped in a proof-of-concept study using the S-protein
and a small test library of five peptides with known
binding affinities for the S-protein [10]. The current
study represents the first application of single-point
SUPREX in a screening project designed to identify
novel protein ligands, and as such it provides the first
measure of the throughput and efficiency of this tech-
nique. The target protein for this study, cyclophilin A
(CypA), is a protein that is overexpressed in lung tumor
cells [11] and appears to be necessary for normal tumor
growth [12]. Thus, tight binding ligands for CypA could
potentially be used as diagnostic imaging agents as well
as lung cancer therapeutics.
Cyclosporin A (CsA), an immunosuppressive drug,
is the most well-studied and tightest-binding CypA
ligand identified to date [13–17]. Unfortunately, biodis-
tribution studies have shown that CsA is ill-suited for
use as an imaging agent as it has been shown in rats to
be rapidly taken up by the liver and excreted in the GI
tract [18]. The immunosuppressive activities of CsA [13]
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One goal of the current work was to identify novel
CypA ligands that might be more amenable to diag-
nostic imaging and therapeutic applications for lung
cancer.
In an attempt to identify novel molecular scaffolds
that bind to CypA, the 880-member Prestwick Chemical
Library (Illkirch, France) was screened. The Prestwick
Chemical Library contains a variety of structurally
diverse compounds with known safety and bioavail-
ability in humans. Over 85% of the compounds in the
library are off-patent drugs that are marketed in a wide
range of therapeutic areas. CsA was also present in the
Prestwick Chemical Library, where it served as a blind
control. This blind control was the only ligand identi-
fied in our assay as a hit. The focus of this report is to
describe the analytical capabilities (i.e., the throughput
and efficiency) of single-point SUPREX.
Experimental
Materials
The CypA (human) used in this work was obtained by
recombinant DNA methods that involved the following
steps: (1) overexpressing the CypA protein as a gluta-
thione S-transferase (GST) fusion protein in E. Coli
(BL21-DE3), (2) purifying the fusion protein using a
GST-binding resin, (3) removing the GST tag in an
overnight incubation with 5 units of thrombin per mg of
fusion protein, and (4) removing the GST and thrombin
with GST-binding resin (Promega Corp., Madison, WI)
and HiTrap Benzamidine FF (Amersham Biosciences,
Piscataway, NJ), respectively. The 880-compound
Prestwick Chemical Library was obtained from the
Small Molecule Synthesis and Screening Facility in
the Center for Chemical Biology at Duke University.
The library compounds were provided as 1 L aliquots
of 1 mM solutions in dimethyl sulfoxide (DMSO). CsA
was purchased from LKT Laboratories (St. Paul, MN).
Myoglobin (horse skeletal muscle), trypsin inhibitor
(soybean), deuterium oxide (D2O; 99.9% atom D), so-
dium deuteroxide (40% by weight in D2O, 99.9% atom
D), and sinapinic acid (SA) were from Sigma (St. Louis,
MO). Phosphoric acid-d3 was purchased from Cam-
bridge Isotope Laboratories, Inc. (Andover, MA), and
guanidinium chloride (GdmCl) was purchased from
EMD Chemicals, Inc. (Gibbstown, NJ). Trifluoroacetic
acid (TFA) was from Halocarbon (River Edge, NJ), and
acetonitrile (ACN) and DMSO were from Fisher (Fair-
lawn, NJ).
Theoretical SUPREX Curves
Equation 1, which was derived in reference [4] for the
analysis of SUPREX data, was used to generate the
theoretical SUPREX curves in this work.Mass  M (M0M) e

kintt
1Kfold
(1)
The variables in eq 1 are defined as follows: mass is
the mass difference between the protonated and deu-
terated forms of the protein, M0 is the mass of the
protein before the protein’s globally protected amide
protons are exchanged with solvent deuterons (i.e., the
mass of the pre-transition baseline of a SUPREX
curve), M is the mass of the protein after all of the
protein’s amide protons have exchanged with solvent
deuterons (i.e., the mass of the post-transition baseline
of a SUPREX curve), kint is the average intrinsic
exchange rate for an unprotected amide proton, t is the
H/D exchange time used in the SUPREX experiment,
and Kfold is given by eq 2.
Kfold e
(Gfm[GdmCl])
RT (2)
The variables in eq 2 are defined as follows: R is the
universal gas constant, T is the temperature, m is
defined as Gf/[denaturant], [GdmCl] is the con-
centration of GdmCl in the exchange buffer, and Gf
is the protein’s folding free-energy in the absence of
denaturant.
In using eqs 1 and 2 to construct the theoretical
SUPREX curve for CypA in the absence of ligand, M0
and M were assigned values of 55 and 95 Da (respec-
tively) based on the experimental data in reference [17],
and kint was assigned a value of 7.08 s
1 based on a
calculation using the program SPHERE, which per-
forms the calculation using model dipeptide data along
with the protein sequence and experimental tempera-
ture and pH values [19, 20]. We set t to 35 min, and m
and Gf were assigned values of 3.7 kcal/(mol M) and
10.4 kcal/mol (respectively) based on an average of the
two sets of values reported for CypA in reference [17].
Construction of the theoretical curves for CypA in
the presence of the hypothetical ligands required the
calculation of a Gf value (i.e., the change in Gf upon
ligand binding) according to eq 3 [21].
GfnRTln1 [L]Kd (3)
In eq 3, [L] is the concentration of free ligand in the
exchange buffer, n is the number of equivalent ligand
binding sites in the protein, Kd is the dissociation
constant of the hypothetical ligand, and R and T are
defined above. In our calculations using eq 3, n was set
to 1 and [L] was set to 90 M, which was the estimated
ligand concentration in the SUPREX buffers. A Gf
value was calculated for CypA complexed with each
hypothetical ligand by adding the corresponding Gf
value for CypA in the presence of each hypothetical
ligand to 10.4 kcal/mol (i.e., the Gf value of the
unbound protein—see above). Ultimately the resulting
Gf values were used in eq 1, as described above, to
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presence of each hypothetical ligand.
Buffer Preparation
A deuterated exchange buffer solution (20 mM phos-
phate, pD 7.4) containing 1.5 M GdmCl was prepared.
The pD of the buffer was adjusted by adding sodium
deuteroxide while monitoring pH using a Jenco micro-
computer pH-Vision 6072 pH meter equipped with a
Futura calomel pH electrode from Beckman (Fullerton,
CA). pH measurements were converted to pD measure-
ments by adding 0.4 to the pH reading [22]. Before
protonated GdmCl was used in the buffers, it was
brought to a deuterium content of 99% by performing
four cycles of dissolution in D2O (19 g GdmCl in 25 mL
D2O) and lyophilization. The final concentration of
GdmCl in the buffer was measured with a refractometer
(Bausch and Lomb, Rochester, NY) using the method
described by Nozaki [23].
Mass Spectrometry
The MALDI matrix was prepared as a saturated SA
solution in an aqueous buffer containing 0.1% TFA and
45% ACN. Internal standards (myoglobin and trypsin
inhibitor) were added directly to the matrix solution.
Mass spectra were acquired on one of two different
MALDI mass spectrometers, including a Voyager Bio-
spectrometry Workstation from PerSeptive Biosystems
(Framingham, MA) and an Ultraflex II TOF/TOF from
Bruker Daltonics (Billerica, MA). The Voyager instru-
ment was employed in the initial screening experiment,
and the Ultraflex instrument, which was not available
for the project during the initial screening, was em-
ployed in the rescreening that was performed as part of
the two-tier strategy (see below). Other than the Ultra-
flex’s ability to collect data more rapidly, the perfor-
mance characteristics (e.g., mass accuracy, precision,
and resolution) were comparable.
All mass spectra were acquired in the linear and
positive ion modes. Spectra collected with the Voyager
instrument were a sum of 32 laser shots from a nitrogen
laser operating at 3 Hz and were collected using the
following instrument parameters: an acceleration volt-
age of 25 kV, a grid voltage of 22.3 kV, a guide wire
voltage of 37.5 V, and a delay time of 300 ns. Spectra
collected with the Ultraflex instrument were a sum of
100 laser shots from a Nd:YAG laser operating at 100
Hz and were collected using the following instrument
parameters: an ion source 1 voltage of 25 kV, an ion
source 2 voltage of 23.35 kV, a lens voltage of 6 kV, and
a delay time of 130 ns.
The mass-to-charge ratio of the CypA peak was
determined using either a Microsoft Excel macro pro-
gram or a MATLAB (The MathWorks, Inc., Natick, MA)
script. Both programs require the input of spectral data
in the form of a text file that contains m/z and intensity
values for each data point in the spectrum. Theseprograms were developed in-house to perform the
following three steps: (1) a 19-point floating average
smoothing of the data, (2) a two-point calibration using
the two internal standards, and (3) a center of mass
calculation for the CypA peak. Each program uses the
[M  H] ion signals of the two calibrants in each
spectrum to generate a linear calibration equation that
is then applied to the CypA ion signal. Ultimately, the
center of mass of the CypA peak is calculated using a
weighted average.
Library Screening
Assay conditions (i.e., the H/D exchange time and
denaturant concentration) for the initial library screen-
ing were chosen such that CypA ligands with Kd values
in the low micromolar range would be selected. An
exchange time of 35 min and a GdmCl concentration of
1.5 M were used here to select compounds with Kd
values 10 M. In theory, the H/D exchange time and
denaturant concentration can be tuned to select tighter
(or weaker) binding ligands. However, the goal of this
study was to select for ligands with Kd values 10 M
(see the Results and Discussion section). In the assay, 1
L of a 1 mM solution of each library ligand (in DMSO)
was combined with 9 L of the deuterated exchange
buffer (which contained 1.5 M GdmCl). A 1-L aliquot
of a protonated stock solution of CypA (100 M) was
added to the resulting 10-L volume of ligand- and
GdmCl-containing deuterated exchange buffer, and the
H/D exchange reaction with CypA was allowed to
proceed for 35 min. Each H/D exchange reaction was
quenched by adding 1 L of the exchange reaction to 9
L of ice-cold matrix solution (see above). Finally, 1 to
2 L of the quenched reaction/matrix solution was
spotted onto a MALDI target. Mass measurements from
five replicate MALDI mass spectra were averaged, and
this average was used to calculate the mass value. The
standard deviations of the mass measurements were
typically 6 Da, or 10% of the mass values. To limit
the effects of differential back exchange (i.e., the loss of
varying numbers of amide deuterons) from sample to
sample, only 12 samples including 10 library com-
pounds, one positive control (CsA, Kd  30-200 nM
[13–17]), and one negative control (DMSO) were ana-
lyzed at a time. H/D exchange reactions were staggered
at 20-min intervals to allow for nearly continuous data
collection (i.e., MALDI-MS spectra were acquired for
each sample set while the subsequent set was undergo-
ing H/D exchange).
Data Analysis
A 9-point central moving average was used to smooth
the control data. This calculation involved an un-
weighted average of each data point with the four
previous and four subsequent data points. This smooth-
ing step helped to adjust for day-to-day variations in
experimental conditions (i.e., temperature and humid-
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back exchange for each sample set. The averaged values
were used to determine a unique cutoff value for each
set of 10 library members.
The moving average strategy described above was
used to calculate an average mass value for the
negative control (i.e., a massavvalue) in each set of 10
library compounds, and this massav value was used to
determine the cutoff for the corresponding dataset. The
cutoff was determined by subtracting a specified num-
ber of standard deviations (i.e., 3.0, 2.5, or 2.0 standard
deviations) from the massav value. A secondMATLAB
program, also developed in-house, was used to identify
samples with mass values less than or equal to the
cutoff value, and these samples were classified as hits.
Z=-factors were calculated using eq 4 as described in
reference [24].
Z ’  1
(3	c 3	c)

cc

(4)
In eq 4, 	c is the standard deviation of the positive
control, 	c is the standard deviation of the negative
control, c is the mean of the positive control, and c
is the mean of the negative control.
Two-Tier Screening Strategy
Preliminary hits from the assay were subjected to an
additional single-point SUPREX analysis as part of a
two-tier screening strategy. The conditions of the re-
screening experiment were similar to those of the initial
screening, except that C18 ZipTips (Millipore, Billerica,
MA) were used to concentrate and desalt the samples
before single-point SUPREX analysis. The incorporation
of ZipTips into the SUPREX protocol has been reported
previously [25]. Briefly, this process involves quench-
ing the H/D exchange reaction with 1 L of a 10%
TFA solution and extracting the proteins from the
H/D exchange buffers using ZipTips that were pre-
equilibrated according to the manufacturer’s instruc-
tions. Bound proteins were then washed with a solution
of 0.1% TFA and eluted with the matrix solution (satu-
rated SA in 50% ACN, 0.1% TFA, 49.9% water) directly
onto the MALDI target. Internal standards were incor-
porated into the matrix solution before the elution step.
This concentration and desalting step was not essential,
but it generally improved the signal-to-noise ratio of the
CypA peak.
Results and Discussion
General Strategy
The single-point SUPREX protocol used for the screen-
ing assay in this work relies on the ability of SUPREX to
detect ligand binding (Figure 1). In a full SUPREX
analysis, aliquots of a fully protonated protein solution
are diluted into a series of deuterated exchange bufferscontaining various concentrations of a chemical dena-
turant. The denaturant serves to shift the protein fold-
ing equilibrium toward the unfolded state. At higher
concentrations of denaturant, a larger fraction of the
protein population is unfolded, resulting in an in-
creased uptake of deuterons and thus an increase in
mass. This mass change (i.e., mass) is monitored by
MALDI-MS. When the protein interacts with a ligand,
the protein is stabilized, and a greater concentration
of denaturant is required to unfold the protein. Thus,
in the presence of a ligand, the midpoint of the
SUPREX transition shifts toward higher denaturant
concentrations.
SUPREX curves such as those shown in Figure 1 can
be used to derive binding free energies and to deter-
mine solution phase dissociation constants (Kd values)
with reasonably high accuracy and precision. However,
it would be relatively time consuming and would
require large amounts of protein to perform full
SUPREX analyses for every member of a chemical
library. The analysis time and amount of protein re-
quired can be significantly reduced by using a single-
point SUPREX protocol in which a mass value is
recorded at a single denaturant concentration for the
protein in the presence of each library compound. If
appropriate conditions (i.e., denaturant concentration
and H/D exchange time) are chosen, the mass value
will be low in the presence of a binding compound and
high in the presence of a nonbinding compound (see
dashed line in Figure 1).
The denaturant concentration and H/D exchange
time used in this work were selected before the assay by
Figure 1. SUPREX-based detection of protein–ligand binding. A
schematic representation of SUPREX curves expected in the ab-
sence and presence of ligand is shown in the bottom half of the
panel. The dashed vertical line represents an appropriate dena-
turant concentration at which to perform a single-point SUPREX
analysis. At this concentration, the separation between the mass
values expected for the protein in the absence and in the presence
of the ligand is largest. Shown in the top half of the panel is a
schematic representation of the experimental conditions used to
generate the theoretical SUPREX curves shown in the bottom half
of the panel.constructing a series of theoretical SUPREX curves (see
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CypA using GdmCl as the denaturant [17]. The effect of
ligand binding on the SUPREX curve for CypA is
illustrated in Figure 2, which shows a series of theoret-
ical curves for CypA in the absence and presence of
several hypothetical ligands with different binding af-
finities. A detailed description of the procedure used to
generate the theoretical SUPREX curves is provided in
the Experimental section. Using the theoretical curves
in Figure 2, we chose a GdmCl concentration of 1.5 M
and an exchange time of 35 min to allow for the
selection of compounds in the library that bind CypA
with a Kd 10 M. We reasoned that ligands with Kd
values up to 10 M would be useful lead compounds
in our search for CypA-targeting lung cancer therapeu-
tics and imaging agents.
One advantage of using single-point SUPREX is that
the assay is flexible and can be adjusted to select for a
wide range of Kd values. Longer H/D exchanges times
and/or higher denaturant concentrations could be used
to select for tighter binding ligands. In theory, there is
no upper or lower limit to the Kd value selection in
single-point SUPREX. However, in practice the upper
limit is defined by the protein and ligand concentra-
tions that are experimentally accessible. For example,
one would need to increase the protein and ligand
concentrations tenfold compared with those used in this
work to select ligands with Kd values 100 M. The
lower Kd value limit is not generally subject to experi-
mental limitations. We also note that in a given single-
point SUPREX selection, tighter binding ligands do not
necessarily yield different mass values than weaker
binding ligands, as long as the ligands have Kd values
within the selection range. For example, in our selection
of CypA ligands with Kd values 10 M, ligands with
Kd values of 1.0, 0.10, and 0.010 M would all be
expected to yield the same 55 Da mass value (see
Figure 2. Theoretical SUPREX curves for CypA in the absence
and in the presence of four hypothetical ligands with various
binding affinities. The arrow denotes the GdmCl concentration
used in the single-point SUPREX analyses performed in this work.Figure 2).Hit Identification
The 880 compounds in the Prestwick Chemical Library
were individually screened for binding to CypA using
single-point SUPREX. Representative data from the
screen is shown in Figure 3a. Note that a positive
control (CsA) and a negative control (DMSO) were
analyzed with every set of 10 ligands in the library.
Mass values were determined for all compounds in
the library except for 18 compounds, all of which
appeared to suppress the MALDI ion signal for CypA.
Shown in Figure 4 are the mass values obtained for
the positive and negative controls that were analyzed
over the course of the screening, which took place in
5-h time blocks spread over a period of several weeks.
The control data were not constant over the time course
of the experiment. Figure 4 shows a random scatter to
the mass values obtained for the controls as well as a
clear trend in the massav values that were calculated
from the control data.
The random scatter of the points in Figure 4 can be
explained by the precision of the molecular weight
determinations of the CypA in this work. Standard
deviations of replicate molecular weight determinations
using our MALDI readout were consistently 6 Da,
whether the protein was protonated, deuterated in the
presence of ligand, or deuterated in the absence of
Figure 3. (a) Representative data from the initial screen per-
formed using the single-point SUPREX assay. Positive and nega-
tive controls are shown as open and filled bars, respectively. The
standard deviations for the mass measurements were typically
10% of the mass values. (b) The rescreening data collected on
the preliminary 41 hits identified in the initial screen using a 3.0
standard deviation cutoff. The dotted lines in both panels repre-
sent the 3.0 standard deviation cutoff, which varied slightly for
each dataset in panel (a) according to the moving average. The
numbered bars represent compounds that were selected as hits in
the initial screening but not in the rescreening, and the arrow
indicates the only hit (i.e., the blind control) that was identified
using the two-tier strategy.
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pected for our MALDI-TOF instrument (200 to 400
ppm). The changes observed in the massav values over
the course of the experiment are most likely due to
variations in the degree of back exchange for each
sample set. This variability in the extent of back ex-
change most likely resulted from day-to-day fluctua-
tions in the temperature and humidity levels of the
laboratory and from variations in the timing of sample
preparation/data collection.
The variability in the control data made the selection
of a constant cutoff value impractical, and it prompted
the development of a new strategy for processing
single-point SUPREX data that involved the use of a
moving average (i.e., massav) to calculate cutoff val-
ues. This moving average strategy was particularly
useful in correcting for the day-to-day and set-to-set
variations in back exchange that we observed. Initially,
a cutoff value of 3 standard deviations below the
massav value of the negative controls (Figure 4) was
used to select hits. This resulted in the selection of 41
preliminary hits.
The 41 preliminary hits were rescreened in a second
single-point SUPREX analysis (Figure 3b). Four positive
and four negative controls were also included in this
analysis. In the rescreening, the four negative control
mass values were averaged to generate a massav
value, and the cutoff was determined by multiplying
the standard deviation of the negative control mass
values by 3 and subtracting this product from the
massav value of the negative control (79 Da). This
calculation resulted in a cutoff of 55 Da, and application
of this cutoff resulted in a single hit. The hit was the
blind control, CsA. It is not surprising that no new hits
were identified in a library of this size; a conservative
estimate of the average rate of confirmed HTS hits is
reported to be 0.1% [26, 27]. Thus, a library of at least
1000 compounds is generally required to identify just
Figure 4. Summary of the positive (filled circles) and negative
(open circles) control data. The upper and lower solid black lines
represent the moving average (massav) of the negative and
positive control data, respectively (see the Experimental section).
The gray line depicts the moving cutoff value, which was set at
three standard deviations below the moving average of the
negative control data.one confirmed hit.Throughput
Assay data were collected during time periods of 5 h
per day over a period of several weeks. In total, it took
3000 min, or about 3 min/ligand, to acquire the mass
spectra for all library compounds and controls using the
Voyager mass spectrometer that was exclusively em-
ployed in the initial screen. Extraction of the mass data
from the5000 mass spectra recorded in this work took
a total of 300 min, and subsequent analysis of the
mass values to ascertain which compounds were hits
was accomplished in 30 min. However, we estimate
that the data analysis time could have been reduced
approximately threefold had we exclusively used the
MATLAB program for extracting mass values from
the spectra. The MATLAB program was developed
during the course of this work and was only employed
in the hit validation component of the screening project.
The Excel-based program, which is approximately ten-
fold slower than the MATLAB program, was employed
in the early stages.
Several factors that impact the throughput of single-
point SUPREX include the exchange time, the size of the
sample set, and the rate at which MALDI mass spectra
can be collected. Long exchange times require a larger
investment of time before mass spectral analysis can
begin. However, as long as H/D exchange reactions are
staggered, the extra time is only invested once at the
beginning of each assay. Increasing the size of each
sample set could improve throughput as well, particu-
larly if the application of a moving average is used to
account for variations in back exchange. In this work,
back exchange effects were minimized by keeping each
sample set small (i.e., each set contained 10 library
compounds, a positive control, and a negative control).
This allowed for the collection of all spectra for each set
within a short period of time (about 15 min). Small
sample sizes also helped to decrease the time required
to pipette samples onto the MALDI target, thereby
minimizing the effects of differential back exchange.
However, we note that 50% of the deuterons that
exchanged into the protein during the H/D exchange
reaction were consistently back-exchanged to protons
during the MALDI sample preparation and analysis
step, as evidenced by the mass values of the negative
controls, which were typically 80 Da. This mass
value represents 50% of the mass gain expected if all
167 amide protons in CypA were exchanged with
solvent deuterons. The use of back exchange correction
factors was investigated in this work (data not shown),
but their use in the data analysis had no impact on the
screening results.
We found that the rate-limiting step in our initial
screen using the Voyager mass spectrometer was the
time required to acquire the MALDI mass spectra. Due
to the low repetition rate of the nitrogen laser (3 Hz)
and the slow sample positioning mechanisms (10
s/sample) in the instrument, 15 min were required to
collect the necessary mass spectra on each dataset of 12
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ment, such as the Ultraflex instrument used in our
rescreening experiments, could result in a dramatic
increase in throughput. Such high throughput instru-
ments have laser repetition rates of 200 Hz and have
fast sample positioning mechanisms (2 s/sample).
Additionally, the use of a high throughput MALDI
instrument might allow for the analysis of larger data-
sets without significantly increasing the time that back
exchange can occur within the mass spectrometer. We
estimate that the use of a high throughput MALDI
instrument for single point SUPREX analyses would
increase the throughput of single-point SUPREX to 20
s/ligand. We note that the Ultraflex instrument was not
used in the initial screening experiment in this work
because it was not available for the project.
One additional approach for increasing the through-
put of single-point SUPREX is to perform the analyses
in a parallel fashion. In this study, each microtiter plate
well contained only one library compound. However,
single-point SUPREX is particularly well-suited for HTS
applications because of its multiplex capabilities. Theo-
retically, multiple ligands could be placed in each well
of the microtiter plate, allowing for the simultaneous
screening of many library compounds at once. For
example, the simultaneous screening of 10 library com-
pounds per well has the potential to create a tenfold
increase in throughput. One caveat to such multiplex-
ing is that for every well that is identified as a hit, the
compounds in the well must be individually retested to
identify which compound(s) were responsible for the
hit. Because of the need for additional analysis of each
hit, the screen would need to be stringent enough to
select for only the tightest binding ligands. The com-
bined use of a high throughput MALDI and a multi-
plexing strategy is expected to produce up to a 100-fold
increase in throughput compared to the 3 min/ligand
observed here. This would make it possible to screen
40,000 compounds in a 24-h day using single-point
SUPREX.
Efficiency
One goal of this work was to determine the efficiency of
the single-point SUPREX protocol. The efficiency is
defined here as the accuracy with which hits can be
identified. One factor that influences efficiency is the
choice of the cutoff value. The cutoff value used in this
work was initially taken as 3 standard deviations below
the massav values for each dataset. The use of three
standard deviations is customary for high throughput
screens [24], but we note that this value could be
adjusted to make the cutoff more or less stringent. For
example, the use of a cutoff value 2.5 standard devia-
tions below the massav of the negative control resulted
in the selection of 54 new preliminary hits in addition to
the 41 preliminary hits selected using the three standard
deviation cutoff. However, we note that a rescreening of
the 54 new preliminary hits yielded no hits.Two important parameters used to define efficiency
are the number of false positives and false negatives
that appear in the screen. The control data provides one
way in which to estimate the rate of false positives and
false negatives. Summarized in Table 1 are the false
positive and false negative rates observed if the 2.5 and
3.0 standard deviation cutoff values described above
are applied to the positive and negative control data. It
is noteworthy that the false positive rate of 0% for the
controls is unchanged regardless of whether the cutoff
is determined using 3.0 or 2.5 standard deviations. In
contrast, the false negative rate is improved by a factor
of two if the cutoff value is calculated using 2.5 instead
of 3.0 standard deviations. Thus, the choice of cutoff
value can be tuned to optimize false positive and false
negative rates. The optimum cutoff values in this work
were determined to be those calculated using 2.5 stan-
dard deviations in each tier (see below).
The false positive rate can also be estimated using
the library members. Out of the 41 preliminary hits
identified in the initial screen, only one was found to
bind CypA when the 41 preliminary hits were re-
screened. This gives a calculated false positive rate of
98%, which is high, especially considering that Hann
and Oprea estimate a false positive rate of 40% in
typical pharmaceutical screens [26]. Interestingly, the
false positive rate for the initial library selection is about
the same (i.e., 99%) if the cutoff value is calculated using
2.5 standard deviations. The false negative rate cannot
be easily calculated using the library members. How-
ever, our selection of CsA suggests that the false nega-
tive rate is low enough for the screen to be effective.
Based on the results obtained with the library mem-
bers, the false positive rates observed in our initial
screening of the 880-member library are quite high (see
one-tier results in Table 1). One approach that can be
used to reduce false positives in HTS assays is to use a
two-tier selection strategy in which preliminary hits
detected in an initial screen are subject to a rescreening
[28]. Such a two-tier selection strategy is especially
useful when the assay readout is subject to random
error, as is the case for the MALDI-MS readout in the
Table 1. Efficiency of single-point SUPREX
False positives False negatives
Controls
3.0 SD cutoff 0/86 (0%) 15/85 (18%)
2.5 SD cutoff 0/86 (0%) 8/85 (9%)
Library compounds (1-tier)
3.0 SD Cutoff 40/41 (98%) —
2.5 SD Cutoff 94/95 (99%) —
Library compounds (2-tier)a
3.0 and 3.0 SD cutoffs 0/1 (0%) —
2.5 and 2.5 SD cutoffs 0/1 (0%) —
2.5 and 3.0 SD cutoffs 0/1 (0%) —
aIn this category, the number of standard deviations used to calculate
the cutoff values are listed for tiers 1 and 2, respectively.single-point SUPREX protocol. If such a two-tier selec-
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library, the false positive rates observed for the single-
point SUPREX protocol are reduced to 0%, regardless of
how the cutoffs are calculated (i.e., using 3.0, 2.5, or a
combination of 2.5 and 3.0 standard deviations).
Our results indicate that a two-tier selection strategy
using 2.5 standard deviations to calculate the cutoff
values in tier one was optimal in this work. The results
for tier two were the same regardless of whether 2.5 or
3.0 standard deviations were used in the calculation of
the cutoff value. As shown in Table 1, the choice of 2.5
standard deviations produced the optimal false positive
and false negative rates for the controls, the lowest false
positive rate in the library screening, and a reasonable
number of preliminary hits (i.e., 10% of the 880 com-
pounds in the library). We note that the use of 2.0
standard deviations to calculate the cutoff value was
also investigated (data not shown); however, this re-
sulted in a large number of preliminary hits (25% of
the 880 ligands in the library), an increased false posi-
tive rate based on the controls, and only a small
improvement in the false negative rate (i.e., from 9% to
7%).
One drawback to the two-tier selection strategy is
that extra time is required for the repeated analyses of
false positives. Our results indicate that the time needed
for such repeat analyses was relatively small (i.e.,10%
of the time required for the preliminary screening)
when the cutoff values in each tier were determined
using 2.5 standard deviations. Moreover, the use of
such a cutoff value only yielded a false negative rate of
9%. This suggests that the likelihood of missing a
specific ligand in the library with a Kd value 10 M
was low (i.e., 10%) and that the likelihood of selecting
a specific ligand in the library with a Kd value 10 M
was high (i.e., 90%).
Another parameter used to judge the efficiency of the
assay is the Z=-factor, which can be calculated using eq
4 [24]. Using the massav and standard deviation for
each control, it was possible to calculate Z=-factors for
all of the control data points that were collected over the
course of our screening. The Z=-factors ranged from
2.1 to 0.2, and the average Z=-factor was 0.7 over the
entire screen. It is noteworthy that the control data
improved over the course of the experiment. For exam-
ple, Z=-factors ranged from0.3 to 0.2 in the last 25% of
the controls, and the average Z=-factor for these controls
was 0.0. This improvement in the Z=-factor is attributed
to an improvement in the timing of the H/D exchange
reactions and mass spectrometry analyses, which de-
creased the variation in back exchange between data-
sets. It has been noted that HTS assays with Z=-factors
0 are generally useful for screening large (e.g.,
100,000-member) combinatorial libraries [24]. Our re-
sults suggest that with optimized timing of the H/D
exchange reactions and mass spectrometry analyses the
single-point SUPREX protocol is capable of screening
such libraries for binding to CypA (i.e., Z=-factors of 0
can be obtained).The Z=-factors in this work were significantly lower
than the Z=-factor calculated in the single-point SUPREX
proof-of-concept study involving the S-protein (Z= 0.77)
[10]. The discrepancy ismost likely due to the difference in
the masses of the target proteins. CypA has a mass of
18.2 kDa, while the mass of the protein used in the
proof-of-concept study (S-protein) was only 11.5 kDa.
Since the absolute precision of MALDI-TOF mass spec-
trometers decreases as protein mass increases, our mass
measurements of CypA were less precise (i.e., standard
deviations of 6 Da) than our mass measurements of
S-protein (i.e., standard deviations of 2 Da). Higher
standard deviations can result in lower Z=-factors. This
makes the use of single-point SUPREX more challenging
for larger proteins. However, the Z=-factor does not solely
depend on the standard deviations of the controls; it also
depends on the difference between the average positive
and negative control values. Thus, the Z=-factor will also
be influenced by the amplitude of the target protein’s
SUPREX curve. Such amplitudes are hard to predict for a
given protein as they are largely defined by the number of
globally protected amide protons (i.e., protons that are
protected by the folded structure of the protein). Because
of this dependence on the amplitude of the SUPREX
curve, we expect the Z=-factor to be different for every
target protein. Thus, larger proteins that have SUPREX
curves with large amplitudes may still be amenable to
single-point SUPREX assays. The amplitude of a SUPREX
curve tends to be slightly larger when short exchange
times are used [9]; therefore, for larger proteins, the
Z=-factor could potentially be improved slightly by adjust-
ing the exchange time.
Another potential strategy for improving the efficiency
of single-point SUPREX for larger proteins involves the
incorporation of a protease digestion step into the proto-
col. Recently, we reported on the use of a rapid (2 min)
protease digestion step to facilitate the SUPREX analyses
of large multidomain proteins [29]. In this SUPREX-
protease digestion protocol the H/D exchange properties
of the individual domains of a protein are defined when
the domains are in the intact protein. However, the
domain-level folding properties are evaluated using pep-
tides generated in the protease digestion step. The stan-
dard deviations associated with peptide molecular weight
determinations by MALDI-TOF mass spectrometry are
typically smaller than those associated with intact protein
molecular weight determinations. These smaller standard
deviations could result in a significant improvement in the
Z=-factor of single-point SUPREX assays. Thus, the future
incorporation of a protease digestion step into the single-
point SUPREX protocol may also improve the efficiency
with which compounds can be screened for binding to
large proteins using SUPREX.
Conclusions
We have demonstrated that a single-point SUPREX
protocol can be used to screen the 880-member
Prestwick Chemical Library for binding to CypA. This
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measure of the throughput of this screening assay,
which was determined to be 3 min/ligand using a
conventional MALDI mass spectrometer equipped with
a nitrogen laser operating at 3 Hz. As part of this
work, we found that the throughput of the single-
point SUPREX protocol was largely limited by the time
needed to acquire the mass spectra in the MALDI
readout. Thus, the use of conventional MALDI mass
spectrometers that have relatively slow sample posi-
tioning mechanisms and nitrogen lasers with relatively
slow repetition rates can create a bottleneck in HTS
projects utilizing the single-point SUPREX protocol.
The use of high throughput MALDI mass spectrometers
equipped with fast sample positioning mechanisms and
high repetition rate lasers could potentially increase the
throughput of the protocol to less than 20 s/ligand. The
data generated in this work also permitted the best
evaluation of the efficiency of single-point SUPREX to
date, and the results suggest that a two-tier selection
strategy is important for minimizing the false positive
and false negative rates of the single-point SUPREX
assay.
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